A. Khakoo, Christos M. Kassiotis, N. Tannir
Jun 1, 2008
Citations
7
Influential Citations
257
Citations
Quality indicators
Journal
Cancer
Abstract
Sunitinib malate is a novel multitargeted receptor tyrosine kinase inhibitor with established efficacy in the treatment of metastatic renal cell carcinoma and imatinib‐resistant gastrointestinal stromal tumor. This report describes the development of heart failure in cancer patients who received this novel agent.